Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Study limitation reported by the research below: “127 patients had no post-final-analysis follow-up and were censored at the prior DCO, which may introduce informative censoring bias.”